Similar Items: The Role of GLP1 Receptor Agonists and Multi-agonist Incretin Therapies for Specific Obesity-related Health Conditions: Evidence and Rationale for Prioritisation
- Metabolic Flux Adaptations During GLP-1 Receptor Agonist Therapy: Redox Implications
- Refining the Bariatric Journey: A Proposed Neoadjuvant and Adjuvant Framework for GLP-1 Receptor Agonists Inspired by Oncology
- Selective Small‐Molecule AdipoR1 Agonist 3‐Hydroxy Pterocarpan Salt (CDRI‐1709S) Ameliorates Skeletal Muscle Atrophy
- Prioritising Indicators for Large-scale Monitoring and Assessment of Food Environments for Public Health
- Beyond the Scale: Setting Goals for Outcomes Beyond Weight in Evidence-based Obesity Treatment
- Digital Mental Health Interventions in Obesity Management: A Systematic Review and Evidence-Based Recommendations